



This product is part of our PureActives® range.

# Puridin® Powder (Cefradine)

## Therapeutical category:

Oral broad-spectrum cephalosporin

## Characteristics:

A crystalline powder. No solvents are used in the process for higher purity and improved odor of the product, with the exception of acetone used for the final product wash. Methanol is used for the side chain activation.

## Applications:

The product is suited for the manufacture of powders and granules for oral suspensions, and tablets. The appropriate excipients should be added.

## PureActives, the enzymatic difference

All our PureActives® antibiotic products are produced using our proprietary, sustainable, and environmentally friendly enzymatic technology. They bring our brand promise to life through superior quality, outstanding reliability and leading sustainability performance.

All our manufacturing sites use the best available technology and operate dedicated waste water treatment plants, 24/7 throughout the year. Effluents are regularly sampled and checked for antimicrobial activity.



Quality



Reliability



Sustainability



## Key parameters: Puridin® Powder (Cefradine)

Pharmacopeia quality	USP, EP, IP, ChP	
Regulatory information	EU:EDQM Bangladesh: MoH Korea: KFDA	China: CFDA Taiwan: DoH
Appearance	White to almost white crystalline powder	
Assay (anhydrous basis)	Cefradine + Cephalexin + Dihydrocefradine: 96.0–102.0% Cefradine: > 90.0%	
pH	3.5 - 6.0	
Water	≤ 6.0%	
Tapped bulk density	≥ 0.55 g/ml	
Total impurities	≤ 2.0%	
Residual solvents	Acetone < 0.2% (washing step)	
Dimethylaniline	Not used in the process	
Shelf-life	Minimum 4 years in the original packaging under recommended storage conditions	
Batch size	Approximately 1000 - 1500 kg	
Storage conditions	At 2 - 8°C, protected from light and moisture	
Packaging	Primary packaging: polyethylene bag	
	Secondary packaging: thermo-sealed aluminum polyethylene bag	
	Outer packaging: corrugated box	
	Fixed quantity of 25 kg packed in each bag; 300 kg per pallet	

### Contact and information

For more information, please visit [www.centrient.com](http://www.centrient.com) or e-mail: [info@centrient.com](mailto:info@centrient.com) or contact us at one of the addresses below:

Rotterdam (HQ)  
[sales@centrient.com](mailto:sales@centrient.com)

Europe/North America  
Delft, The Netherlands  
[sales.ea@centrient.com](mailto:sales.ea@centrient.com)

Asia Pacific / Middle East / Africa  
Gurgaon, India  
[sales.amea@centrient.com](mailto:sales.amea@centrient.com)

China  
Beijing, P.R. China  
[sales.china@centrient.com](mailto:sales.china@centrient.com)

Mexico & Latin America  
Ramos Arizpe, Mexico  
[sales.mla@centrient.com](mailto:sales.mla@centrient.com)

Copyright © 2019 Centrient Pharmaceuticals. All rights reserved. Although diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein can be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor can it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement.

The content of this document is subject to change without further notice. Please contact us for the latest version of this document or further information. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions like the Bolar provisions in the US and 2004/27/EC in Europe.

VAPFS 2019